Abstract
Human neurofibromatosis type 1 is a dominant disease caused by the inheritance of a mutant allele of the NF1 gene. In order to study NF1 function, we have constructed a mouse strain carrying a germline mutation in the murine homologue. Heterozygous animals do not exhibit the classical symptoms of the human disease, but are highly predisposed to the formation of various tumour types, notably phaeochomocytoma, a tumour of the neural crest–derived adrenal medulla, and myeloid leukaemia, both of which occur with increased frequency in human NF1 patients. The wild–type Nf1 allele is lost in approximately half of the tumours from heterozygous animals. In addition, homozygosity for the Nf1 mutation leads to abnormal cardiac development and mid–gestational embryonic lethality.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stumph, D.A. et al. Neurofibromatosis. Arch. Neurol. 45, 575–578 (1987).
Riccardi, V.M., M.D. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. (Johns Hopkins University, Baltimore, 1992).
Hope, D.G. & Mulvihill, J.J. Malignancy in neurofibromatosis. Adv. Neurol. 29, 33–55 (1981).
Bolande, R.P. The neurocristopathies: a unifying concept of disease arising in neural crest maldevelopment. Hum. Pathol. 5, 409–429 (1974).
Cawthon, R.M. et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62, 193–201 (1990).
Viskoshil, D. et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187–192 (1990).
Wallace, M.R. et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249, 181–186 (1990).
Xu, G. et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62, 599–608 (1990).
Martin, G.A. et al. The GAP–related domain of the neurofibromatosis type 1 gene product Interacts with ras p21. Cell 63, 843–849 (1990).
Xu, G. et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63, 835–841 (1990).
Ballester, R. et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63, 851–859 (1990).
DeClue, J.E., Cohen, B.D. & Lowy, D.R. Identification and characterization of the neurofibromatosis type 1 protein product. Proc. natn. Acad. Sci. U.S.A. 88, 9914–9918 (1991).
Basu, T.N. et al. Aberrant regulation of ras proteins in malignant tumur cells from type 1 neurofibromatosis patients. Nature 356, 713–715 (1992).
Daston, M.M. & Ratner, N. Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitiously expressed during development. Devel. Dynamics 195, 216–226 (1992).
Huynh, D.P., Nechiporuk, T. & Pulst, S.M. Differential expression and tissue distribution of type I and type II Neurofibromins during mouse fetal development. Devel. Biol. 161, 538–551 (1994).
Daston, M.M. et al. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, schwann cells, and oligodendrocytes. Neuron 8, 415–428 (1992).
Seizinger, B.R. NF1 :aprevalent cause of tumourigenesisin human cancers? Nature Genet. 3, 97–99 (1993).
Knudson, J.A.G. Mutation and cancer statistical study of retinoblastoma. Proc. natn. Acad. Sci. U.S.A. 68, 820–823 (1971).
Legius, E., Marchuk, D.A., Collins, F.S. & Glover, T.W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nature Genet. 3, 122–126 (1993).
DeClue, J.E. et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69, 265–273 (1992).
Li, Y. et al. Somatic mutations in the neurofibromatosis 1 gene in human tumours. Cell 69, 275–281 (1992).
Andersen, L.B. et al. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nature Genet. 3, 118–121 (1993).
Johnson, M.R., Look, A.T., DeClue, J.E., Valentine, M.B. & Lowy, D.R. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without Impaired regulation of GTP ras. Proc. natn. Acad. Sci. U.S.A. 90, 5539–5543 (1993).
The, I. et al. Neurofibromatosis type 1 gene mutations in neuroblatoma. Nature Genet. 3, 62–66 (1993).
Bernards, A., Snijders, A.J., Hannigan, G.E., Murthy, A.E. & Gusella, J.F. Mouse neurofibromatosis type 1 cDNA sequence reveals high degree of conservation of both coding and non-coding mRNA segments. Hum. molec. Genet. 2, 645–650 (1993).
Brannan, C.I. et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Devel. 8, 1019–1029 (1994).
Estivill, X., Lazaro, C., Casals, T. & Ravella, A. Recurrence of a nonsense mutation In the NF1 gene causing classical neurofibromatosis type 1. Hum. Genet. 88, 185–188 (1991).
Ainsworth, P.J., Rodenhiser, D.I. & Costa, M.T. Identification and characterization of sporadic and Inherited mutations In exon 31 of the neurofibromatosis (NF1) gene. Hum. Genet. 91, 151–156 (1993).
Mansour, S.L., Thomas, K.R. & Capecchi, M.R. Disruption of the protoonco gene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 336, 348–352 (1988).
Gossler, A., Doetschman, T., Korn, R., Serfling, E. & Kemier, R. Transgenesis by means of blastocyst-derived embryonic stem cell lines. Proc. natn. Acad. Sci. U.S.A. 83, 9065–9069 (1986).
Bronson, R.T. Rate of occurrence of lesions in 20 inbred and hybrid genotypes of rats and mice sacrificed at 6 month intervals during the first years of life. In Genetics of Aging II, (ed. Harrison, D.E.) 280–358 (Telford, New Jersey, 1990).
Riccardi, V.M. von Recklinghausen neurofibromatosis. New Engl. J. Med. 305, 1617–1627 (1981).
Chetty, R. & Duhig, J.D. Bilateral pheochromocytoma-ganglioneuroma of the adrenal In type 1 neuroflbromatosis. Am. J. surg. Pathol. 17, 837–841 (1993).
Le Douarin, N.M. The Neural Crest. (Cambridge University, Cambridge, 1982).
Shannon, K.M., Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. New Engl. J. Med. 330, 597–601 (1994).
Kirby, M.L., Gale, T.F. & Stewart, D.E. Neural crest cells contribute to aorticopulmonary septation. Science 220, 1059–1061 (1983).
Xu, W. et al. Loss of NF1 alleles in pheochromocytoma from patients with type I neurofibromatosis. Genes Chrom. Cancer 4, 337–342 (1992).
Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295–300 (1992).
Lee, E.Y.Y.-H.P. et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359, 288–295 (1992).
Clarke, A.R. et al. Requirement for a functional Rb-1 gene in murine development. Nature 359, 328–330 (1992).
Hooper, M., Hardy, K., Handyside, A., Hunter, S. & Monk, M. HPRT-deflcient (Leech-Nyhan)mouse embryos derived from germline colonization by cultured cells. Nature 326, 292–295 (1987).
Keuhn, M.R., Bradley, M., Robertson, E.J. & Evans, M.J. A potential animal model for Lesoh-Nyhan Syndrome through introduction of HPRT mutations into mice. Nature 326, 295–298 (1987).
Easton, D.F., Ponder, M.A., Huson, S.M. & Ponder, B.A.J. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am. J. hum. Genet. 53, 305–313 (1993).
Hinrichs, S.H., Nerenberg, M., Reynolds, R.K., Khoury, G. & Jay, G. A transgenic mouse model for human neurofibromatosis. Science 237, 1340–1343 (1987).
Green, J.E., Baird, A.M., Hinrichs, S.H., Klintworth, G.K. & Jay, G. Adrenal medullary tumors and Iris proliferation in a transgenic mouse model of neuroflbromatosis. Am. J. pathol. 140, 1401–1410 (1992).
Kirby, M.L. & Waldo, K.L. Role of neural crest In congenital heart disease. Circulation 82, 332–340 (1990).
Epstein, D.J., Vekemans, M. & Gros, P. splotch (Sp2H), a mutation affecting development of the mouse neural tube, shows a deletion within the paired homeodomain of Pax-3. Cell 67, 767–774 (1991).
Franz, T. Persistent truncus arteriosus in the Splotch mutant mouse. Anat. Embryol. 180, 457–464 (1989).
Gutmann, D.H., Andersen, L.B., Cole, J.L., Swaroop, M. & Collins, F.S. An alternatively-spliced mRNA in the carboxy terminus of the neurofibromatosis type 1 (NF1) gene is expressed in muscle. Hum. molec. Genet. 2, 989–992 (1993).
Tassabehji, M. et al. Tandem duplication within a Neuroflbromatosis type I (NF1) gene exon in a family with features of Watson Syndrome and Noonan Syndrome. Am. J. hum. Genet. 53, 90–95 (1993).
Thomas, K.R. & Capecchi, M.R. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51, 503–512 (1987).
Shackleford, G.M. & Varmus, H.E. Expression of the proto-oncogene int-1 is restricted to postmeiotic male germ cells and the neural tube of mid-gestational embryos. Cell 50, 89–95 (1987).
Robertson, E.J. Embryo-derived stem cell lines. In Teratocarcinomas and embryonic stem cells: a practical approach, (ed. Roberton, E.J.) 77–78 (IRL, Oxford, 1987).
Xie, W.-Q. & Rothblum, L.I. Rapid, small-scale RNA isolation from tissue culture cells. BioTechniques 11, 325–327 (1991).
Ausubel, F.M. et al. Current Protocols in Molecular Biology (Wiley, Boston, 1994).
Laird, P.W. et al. Simplified mammalian DNA Isolation procedure. Nucl. Acids Res. 19, 4293 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jacks, T., Shih, T., Schmitt, E. et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7, 353–361 (1994). https://doi.org/10.1038/ng0794-353
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0794-353
This article is cited by
-
Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1
Nature Communications (2022)
-
An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies
Cardiovascular Drugs and Therapy (2022)
-
Shared developmental gait disruptions across two mouse models of neurodevelopmental disorders
Journal of Neurodevelopmental Disorders (2021)
-
MEK inhibition exerts temporal and myeloid cell-specific effects in the pathogenesis of neurofibromatosis type 1 arteriopathy
Scientific Reports (2021)
-
Model systems in SDHx-related pheochromocytoma/paraganglioma
Cancer and Metastasis Reviews (2021)